Hepner G W, Vesell E S
Ann Intern Med. 1975 Nov;83(5):632-8. doi: 10.7326/0003-4819-83-5-632.
The rate of hepatic metabolism of dimethylaminoantipyrine (aminopyrine), which occurs primarily through N-demethylation, was assessed by measurement of the specific activity of 14CO2 excreted in breath samples obtained 2 hours after oral administration of a trace dose of [14C]aminopyrine. The percentage of administered 14C excreted in 14CO2 in 2 hours was 7.0 +/- 1.3 (SD)% in control patients, and significantly less (P less than 0.01) in patients with portal cirrhosis (2.6 +/- 1.2%), fatty liver (4.7 +/- 1.1%), hepatitis (2.6 +/- 1.4%), and hepatic malignancy (3.5 +/- 1.8%). In 16 of 24 subjects with cholestasis not caused by malignant disease the mean 14CO2 excretion was normal. The 14CO2 excretion in patients with portal cirrhosis correlated highly with aminopyrine metabolic clearance rate (r equals 0.92), serum albumin (r equals 0.75), and retention of bromsulphalein (r equals 0.73). Abnormal 14CO2 excretion returned to normal in patients with hepatitis, when the hepatitis resolved. The data suggest that the aminopyrine breath test is a safe, simple, qualitative and quantitative liver function test.
二甲氨基安替比林(氨基比林)的肝脏代谢率主要通过N-去甲基化发生,通过测量口服微量[14C]氨基比林2小时后采集的呼气样本中排出的14CO2的比活性来评估。在对照患者中,2小时内以14CO2形式排出的给药14C的百分比为7.0±1.3(标准差)%,而在门脉性肝硬化患者(2.6±1.2%)、脂肪肝患者(4.7±1.1%)、肝炎患者(2.6±1.4%)和肝脏恶性肿瘤患者(3.5±1.8%)中显著降低(P<0.01)。在24例非恶性疾病引起的胆汁淤积患者中,有16例的平均14CO2排泄正常。门脉性肝硬化患者的14CO2排泄与氨基比林代谢清除率(r = 0.92)、血清白蛋白(r = 0.75)和酚四溴酞磺酸钠潴留(r = 0.73)高度相关。肝炎患者肝炎消退时,异常的14CO2排泄恢复正常。数据表明,氨基比林呼气试验是一种安全、简单的定性和定量肝功能试验。